Literature DB >> 21757741

Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Mar Mora-Santos1, M Cristina Limón-Mortés, Servando Giráldez, Joaquín Herrero-Ruiz, Carmen Sáez, Miguel Á Japón, Maria Tortolero, Francisco Romero.   

Abstract

PTTG1, also known as securin, is an inactivating partner of separase, the major effector for chromosome segregation during mitosis. At the metaphase-to-anaphase transition, securin is targeted for proteasomal destruction by the anaphase-promoting complex or cyclosome, allowing activation of separase. In addition, securin is overexpressed in metastatic or genomically instable tumors, suggesting a relevant role for securin in tumor progression. Stability of securin is regulated by phosphorylation; some phosphorylated forms are degraded out of mitosis, by the action of the SKP1-CUL1-F-box protein (SCF) complex. The kinases targeting securin for proteolysis have not been identified, and mechanistic insight into the cause of securin accumulation in human cancers is lacking. Here, we demonstrate that glycogen synthase kinase-3β (GSK3β) phosphorylates securin to promote its proteolysis via SCF(βTrCP) E3 ubiquitin ligase. Importantly, a strong correlation between securin accumulation and GSK3β inactivation was observed in breast cancer tissues, indicating that GSK3β inactivation may account for securin accumulation in breast cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757741      PMCID: PMC3191045          DOI: 10.1074/jbc.M111.232330

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Dual inhibition of sister chromatid separation at metaphase.

Authors:  O Stemmann; H Zou; S A Gerber; S P Gygi; M W Kirschner
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

2.  A phosphorylation-driven ubiquitination switch for cell-cycle control.

Authors:  J Wade Harper
Journal:  Trends Cell Biol       Date:  2002-03       Impact factor: 20.808

Review 3.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

4.  Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product.

Authors:  F Ramos-Morales; A Domínguez; F Romero; R Luna; M C Multon; J A Pintor-Toro; M Tortolero
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

5.  Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase.

Authors:  F Romero; M C Multon; F Ramos-Morales; A Domínguez ; J A Bernal; J A Pintor-Toro; M Tortolero
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

6.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.

Authors:  Ana Martinez; Mercedes Alonso; Ana Castro; Concepción Pérez; Francisco J Moreno
Journal:  J Med Chem       Date:  2002-03-14       Impact factor: 7.446

7.  Securin is required for chromosomal stability in human cells.

Authors:  P V Jallepalli; I C Waizenegger; F Bunz; S Langer; M R Speicher; J M Peters; K W Kinzler; B Vogelstein; C Lengauer
Journal:  Cell       Date:  2001-05-18       Impact factor: 41.582

Review 8.  GSK3 takes centre stage more than 20 years after its discovery.

Authors:  S Frame; P Cohen
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

9.  Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis.

Authors:  A Zur; M Brandeis
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

10.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Authors:  Tiebang Kang; Yongkun Wei; Yuchi Honaker; Hiroshi Yamaguchi; Ettore Appella; Mien-Chie Hung; Helen Piwnica-Worms
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

View more
  9 in total

1.  Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1.

Authors:  Litian Yin; Zhongmei He; Bing Yi; Linyuan Xue; Jianxin Sun
Journal:  Front Pharmacol       Date:  2020-11-04       Impact factor: 5.810

2.  SIRT3 Blocks Aging-Associated Tissue Fibrosis in Mice by Deacetylating and Activating Glycogen Synthase Kinase 3β.

Authors:  Nagalingam R Sundaresan; Samik Bindu; Vinodkumar B Pillai; Sadhana Samant; Yong Pan; Jing-Yi Huang; Madhu Gupta; Raghu S Nagalingam; Donald Wolfgeher; Eric Verdin; Mahesh P Gupta
Journal:  Mol Cell Biol       Date:  2015-12-14       Impact factor: 4.272

3.  Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.

Authors:  Jhen-Wei Ruan; Yi-Chu Liao; Ingrid Lua; Ming-Hsun Li; Chih-Yi Hsu; Ji-Hshiung Chen
Journal:  Breast Cancer Res       Date:  2012-07-12       Impact factor: 6.466

4.  Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.

Authors:  Xiaosheng Wu; Mary Stenson; Jithma Abeykoon; Kevin Nowakowski; Lianwen Zhang; Joshua Lawson; Linda Wellik; Ying Li; Jordan Krull; Kerstin Wenzl; Anne J Novak; Stephen M Ansell; Gail A Bishop; Daniel D Billadeau; Kah Whye Peng; Francis Giles; Daniel M Schmitt; Thomas E Witzig
Journal:  Blood       Date:  2019-05-17       Impact factor: 25.476

5.  Computational prediction and analysis of breast cancer targets for 6-methyl-1, 3, 8-trichlorodibenzofuran.

Authors:  Kumaraswamy Naidu Chitrala; Suneetha Yeguvapalli
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

6.  Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer.

Authors:  Qiongle Peng; Liuyang Zhao; Yixuan Hou; Yan Sun; Liyang Wang; Haojun Luo; Huimin Peng; Manran Liu
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.

Authors:  Hai-qian Liang; Ren-jie Wang; Cai-feng Diao; Jian-wei Li; Jing-liang Su; Sai Zhang
Journal:  Oncotarget       Date:  2015-10-06

8.  Separase is a marker for prognosis and mitotic activity in breast cancer.

Authors:  Natalia Gurvits; Eliisa Löyttyniemi; Marjukka Nykänen; Teijo Kuopio; Pauliina Kronqvist; Kati Talvinen
Journal:  Br J Cancer       Date:  2017-08-31       Impact factor: 7.640

9.  6-Bromoindirubin-3'-oxime intercepts GSK3 signaling to promote and enhance skeletal muscle differentiation affecting miR-206 expression in mice.

Authors:  Elvira Ragozzino; Mariarita Brancaccio; Antonella Di Costanzo; Francesco Scalabrì; Gennaro Andolfi; Luca G Wanderlingh; Eduardo J Patriarca; Gabriella Minchiotti; Sergio Altamura; Vincenzo Summa; Francesca Varrone
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.